NCT05945524招募中不适用
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 36
- 主要终点
- Response to teclistamab at 12 weeks
研究概览
简要总结
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •With multiple myeloma
- •Who receive Teclistamab
- •Consent form signed
排除标准
- •Patient under legal protection
结局指标
主要结局
Response to teclistamab at 12 weeks
时间窗: at day 1 Cycle 4 (each cycle is 28 days)
response according to International Myeloma Working Group criteria
次要结局
未报告次要终点
研究者
研究点 (36)
Loading locations...
相似试验
已完成
不适用
Bloodstream Infection of Carbapenem-Resistant Proteus MirabilisProteus Mirabilis InfectionCarbapenem Resistant Bacterial InfectionBacteremiaNCT06542965Dokuz Eylul University67
招募中
不适用
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung CancerLung NeoplasmsNCT01580982University of Colorado, Denver500
已完成
4 期
The Immunological Basis for Treatment Resistance to Anti-TNF TreatmentsPsoriasisNCT01971346University of Michigan50
Unknown
2 期
Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabTransitional Cell Carcinoma of the BladderBiomarkersNCT03263039Erasmus Medical Center80
尚未招募
不适用
Disease causing ability, and medical effects of bacterial infections in ICU to understand challenges and opportunities for prevention.CTRI/2021/07/035228Manipal Academy of Higher Education Manipal